8-K: Turn Therapeutics Secures Capital, Advances GX-03 Trial

Turn Therapeutics reported full-year 2025 financial results, secured $25 million in growth capital, and announced progress on its Phase 2 GX-03 trial.

Summary

• Reported full-year 2025 financial and operating results.
• Secured up to $25 million in growth capital from Avenue Capital Group, extending cash runway through the end of 2027.
• Phase 2 trial for GX-03 in moderate-to-severe atopic dermatitis remains on track, with topline results expected mid-2026.
• Appointed Dr. Robert Redfield, former CDC Director, to provide strategic guidance on GX-03 development and regulatory path.
• Appointed Martin Dewhurst to the Board of Directors, bringing over 30 years of life sciences strategy and M&A experience.
• Entered into a global supply, development, and license agreement with Medline in Q4 2025, with revenue generation expected in late 2026.
• Expanded intranasal vaccine pipeline to include an intranasal Influenza candidate.
• Reported a net loss of $3.19 million for the year ended December 31, 2025, compared to $1.77 million in 2024.
• Cash and cash equivalents were $5.08 million as of December 31, 2025, which excludes the receipt of $7.0 million in gross proceeds from the facility with Avenue Capital.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but overall constructive update. While financial losses widened, the successful capital raise and on-track clinical progress for GX-03 provide crucial runway and validation for its lead program, balancing the increased operational burn.

Positives

• Secured up to $25 million in growth capital from Avenue Capital Group, extending cash runway through the end of 2027.
• Phase 2 trial for GX-03 in moderate-to-severe atopic dermatitis is on track for topline results in mid-2026.
• Appointment of Dr. Robert Redfield, former CDC Director, to provide strategic guidance on GX-03 development and regulatory path.
• Appointment of Martin Dewhurst to the Board of Directors, adding significant life sciences strategy and M&A expertise.
• Global license, supply, and distribution agreement with Medline creates an opportunity to begin generating revenue in late 2026.
• Expansion of the intranasal vaccine pipeline to include an intranasal Influenza candidate.
• Total stockholders' equity improved from a deficit of $(177,432) in 2024 to a positive $4,686,723 in 2025.

Negatives

• Net loss increased to $3.19 million for the year ended December 31, 2025, from $1.77 million in 2024.
• Loss from operations increased to $5.86 million in 2025 from $1.80 million in 2024.
• General and administrative expenses significantly increased to $5.5 million in 2025 from $1.5 million in 2024, primarily due to costs associated with the public listing.
• Basic and diluted net loss per common share increased to $(0.12) in 2025 from $(0.07) in 2024.

Risks

• Inherent uncertainties, risks, and assumptions that are difficult to predict.
• Risks related to the timing and effectiveness of the Company's registration statement.
• Risks related to the success of development programs.
• Risks related to the Company's ability to execute its strategic plan.
• Certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.

Future Outlook

Turn Therapeutics expects topline results for its Phase 2 trial of GX-03 in moderate-to-severe atopic dermatitis by mid-2026. The company anticipates beginning to generate revenue in late 2026 through its agreement with Medline and projects its cash runway to extend through the end of 2027 following the recent capital raise.

Management Comments

• "Our first months as a public company have been highly productive, with strong progress across our clinical, financial, and strategic priorities."
• "Our Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis remains on track for topline results in mid-2026, positioning us to advance a potential first-line therapy in atopic dermatitis."
• "Securing up to $25 million in growth capital from Avenue Capital extends our expected runway through the end of 2027 and supports focused investment in the Company's therapeutic programs."
• "In parallel, our global license, supply, and distribution agreement with Medline creates the opportunity to begin generating revenue in late 2026 while also validating the commercial viability of our technology across multiple applications."

Industry Context

StockSavvy.ai notes that the biotechnology sector, particularly clinical-stage companies focused on dermatologic conditions, often relies heavily on successful clinical trial progression and strategic partnerships for validation and funding. Turn Therapeutics' progress with its Phase 2 GX-03 trial and the Medline agreement are critical milestones that could enhance its competitive position against other dermatology-focused biotechs. The appointment of high-profile advisors like Dr. Redfield is a common strategy to bolster credibility and navigate complex regulatory landscapes in drug development.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value if GX-03 trial results are positive and Medline agreement generates significant revenue; extended cash runway reduces immediate going concern risk.
• Employees: Continued employment and investment in therapeutic programs.
• Customers (future): Potential for new treatment options for atopic dermatitis and other inflammatory conditions.
• Creditors: Avenue Capital Group is a new creditor with a venture debt facility.

Next Steps

• Topline results for Phase 2 trial of GX-03 in moderate-to-severe atopic dermatitis expected mid-2026.
• Potential drawing of two additional tranches totaling up to $18 million from the venture debt facility, subject to milestones and criteria.
• Opportunity to begin generating revenue in late 2026 from the global supply, development, and license agreement with Medline.
• Continued development of GX-03 in atopic dermatitis and onychomycosis.
• Further development of the intranasal Influenza candidate.

Key Dates

Recommendation

While Turn Therapeutics reported increased losses, the securing of significant growth capital and the on-track progress of its lead clinical asset, GX-03, provide a crucial lifeline and potential catalysts. The Medline agreement also offers a near-term revenue opportunity. However, the company remains clinical-stage with no current revenue, and future success hinges on positive trial outcomes and successful commercialization. The increased G&A expenses also warrant monitoring. A 'hold' recommendation is appropriate as investors await key clinical data and revenue generation, balancing the positive strategic developments against the current financial burn.

Keywords

Turn Therapeutics, TTRX, biotechnology, atopic dermatitis, eczema, GX-03, Phase 2 trial, clinical-stage, dermatology, inflammatory diseases, immunology therapies, venture debt, capital raise, Medline agreement, intranasal vaccine, PermaFusion, financial results, corporate updates, biopharma